Pill Identifier App

Generic Ultane Availability

Ultane is a brand name of sevoflurane, approved by the FDA in the following formulation(s):

ULTANE (sevoflurane - liquid; inhalation)

  • Manufacturer: ABBVIE
    Approval date: June 7, 1995
    Strength(s): 100% [RLD] [AN]

Has a generic version of Ultane been approved?

A generic version of Ultane has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Ultane and have been approved by the FDA:

sevoflurane liquid; inhalation

  • Manufacturer: BAXTER HLTHCARE
    Approval date: July 2, 2002
    Strength(s): 100% [AN]
  • Manufacturer: HALOCARBON PRODS
    Approval date: November 19, 2007
    Strength(s): 100% [AN]

SOJOURN (sevoflurane liquid; inhalation)

  • Manufacturer: PIRAMAL CRITICAL
    Approval date: May 2, 2007
    Strength(s): 100% [AN]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ultane. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
    Patent 5,990,176
    Issued: November 23, 1999
    Inventor(s): Bieniarz; Christopher & Chang; Steve H. & Cromack; Keith R. & Huang; Shuyen L. & Kawai; Toshikazu & Kobayashi; Manami & Loffredo; David & Raghavan; Rajagopalan & Speicher; Earl R. & Stelmach; Honorate A.
    Assignee(s): Abbott Laboratories Central Glass Company Ltd.
    The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.
    Patent expiration dates:
    • January 27, 2017
    • July 27, 2017
      ✓ 
      Pediatric exclusivity
  • Container for an inhalation anesthetic
    Patent 6,074,668
    Issued: June 13, 2000
    Inventor(s): Flament-Garcia; Mary Jane & Chang; Steve H. & Cromack; Keith R. & Garapolo; Joan & Loffredo; David & Raghavan; Rajagopalan & Ramsay; George M. & Rice; Patrick & Setesak; Jeffrey
    Assignee(s): Abbott Laboratories
    A pharmaceutical product. The pharmaceutical product includes a container constructed from a material containing polyethylene napthalate. The container defines an interior space. A volume of a fluoroether-containing inhalation anesthetic is contained in the interior space defined by the container.
    Patent expiration dates:
    • January 9, 2018
    • July 9, 2018
      ✓ 
      Pediatric exclusivity
  • Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
    Patent 6,288,127
    Issued: September 11, 2001
    Inventor(s): Bieniarz; Christopher & Chang; Steve H. & Cromack; Keith R. & Huang; Shuyen L. & Kawai; Toshikazu & Kobayashi; Manami & Loffredo; David & Raghavan; Rajagopalan & Speicher; Earl R. & Stelmach; Honorate A.
    Assignee(s): Abbott Laboratories & Central Glass Co LTD
    The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.
    Patent expiration dates:
    • January 27, 2017
    • July 27, 2017
      ✓ 
      Pediatric exclusivity
  • Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
    Patent 6,444,859
    Issued: September 3, 2002
    Inventor(s): Christopher; Bieniarz & Steve H.; Chang & Keith R.; Cromack & Shuyen L.; Huang & Toshikazu; Kawai & Manami; Kobayashi & David; Loffredo & Rajagopalan; Raghavan & Earl R.; Speicher & Honorate A.; Stelmach
    Assignee(s): Abbott Laboratories Central Glass Company LTD
    The present invention relates to an anesthetic composition containing a fluoroether compound and a physiologically acceptable Lewis acid inhibitor. This composition exhibits improved stability and does not readily degrade in the presence of a Lewis acid.
    Patent expiration dates:
    • January 27, 2017
    • July 27, 2017
      ✓ 
      Pediatric exclusivity

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ANSolutions and powders for aerosolization. Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in any of several delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded AN. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded BN, unless they have met an appropriate bioequivalence standard. Solutions or suspensions in a specific delivery system will be coded AN if the bioequivalence standard is based upon in vitro methodology, if bioequivalence needs to be demonstrated by in vivo methodology then the drug products will be coded AB.
Advertisement
Close

Recommended

(web1)